Inova Pharmaceuticals(singapore) PT Pharmaceutical Import Profile — Singapore (DGFT 2022–2026)

Name: Inova Pharmaceuticals(singapore) PT Pharmaceutical Import Records from India — 2 Products, $635.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Inova Pharmaceuticals(singapore) PT — Pharmaceutical Importer Profile (2026) | 2 Products, $635.9K Trade | TransData Nexus

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Extract	Ayurvedic & Herbal Products	$402.1K	44	3.3%	4
2	Bromhexine	Respiratory & OTC	$233.9K	17	1.4%	8

Inova Pharmaceuticals(singapore) PT imports 2 pharmaceutical products across 2 categories into Singapore totaling $635.9K.

Inova Pharmaceuticals(singapore) PT — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Inova Pharmaceuticals (Singapore) Pte. Limited, established on November 23, 2006, is a private company headquartered at 1 Temasek Avenue, #04-01, Millenia Tower, Singapore 039192. The company specializes in the sales and marketing of Western medicinal and pharmaceutical products, focusing on both consumer health brands and prescription medicines. Its portfolio spans key therapeutic areas such as throat, cough, cold & flu, skin care, sun care, pain management, wound care, weight management, and natural health supplements. Operating across over 75 markets, Inova Pharmaceuticals emphasizes innovative healthcare solutions to enhance global health and well-being. (companies.sg)

2Distribution Network

While specific details about Inova Pharmaceuticals' warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive distribution network across over 75 markets suggests a robust infrastructure. This network likely includes strategically located warehouses and efficient logistics operations to ensure timely delivery of pharmaceutical products. The geographic coverage spans Asia, Australia, New Zealand, the Middle East, Africa, and Europe, indicating a well-established and expansive distribution system. (inovapharma.asia)

3Industry Role

Inova Pharmaceuticals (Singapore) Pte. Limited functions primarily as a wholesaler and distributor within Singapore's pharmaceutical supply chain. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from India, and subsequently distributes these products to various stakeholders in the healthcare sector. This role positions Inova Pharmaceuticals as a key intermediary between international manufacturers and the local market, facilitating the availability of diverse pharmaceutical products in Singapore.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Inova Pharmaceuticals(singapore) PT

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Inova Pharmaceuticals' sourcing strategy reveals a concentrated dependency on a limited number of products imported from India. The company's total import value from India stands at $636,000 USD, encompassing 61 shipments of two distinct products across two therapeutic categories. The top five products imported include Extract ($402,000 USD) and Bromhexine ($234,000 USD), accounting for 3.3% and 1.4% of the total import value, respectively. This concentration indicates a strategic choice to focus on specific high-demand products, potentially streamlining operations and strengthening supplier relationships. However, such dependency may also pose risks related to supply chain disruptions or market fluctuations affecting these particular products.

2Supply Chain Resilience

The resilience of Inova Pharmaceuticals' supply chain, particularly concerning its Indian suppliers, is not explicitly detailed in the available data. The company's concentrated sourcing strategy suggests a reliance on specific suppliers for its key products. While this focus can lead to stronger partnerships and potentially better terms, it also exposes the company to risks associated with supply chain disruptions, such as production delays or regulatory changes in India. The lack of publicly available information on backup suppliers and the diversity of formulations imported makes it challenging to fully assess the supply chain's resilience.

Importing Pharmaceuticals into Singapore — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Singapore

1Regulatory Authority & Framework

In Singapore, the Health Sciences Authority (HSA) is the primary regulatory body overseeing the importation, supply, and manufacture of health products, including pharmaceuticals. Established as a statutory board under the Ministry of Health, HSA ensures that all health products meet standards of safety, quality, and efficacy. The regulatory framework governing pharmaceutical imports includes the Health Products Act and the Medicines Act, along with their subsidiary legislation, which may encompass requirements for product registration and dealer's licensing. (moh.gov.sg)

2Import Licensing & GMP

Importers of pharmaceutical products into Singapore must comply with the Health Products Act and the Medicines Act, which require product registration and dealer's licensing. The Health Sciences Authority (HSA) evaluates and approves all medicines, including generics, for safety, quality, efficacy, and compliance with Good Distribution Practice standards before they can be supplied in Singapore. Recognized Good Manufacturing Practice (GMP) certifications, such as EU GMP, WHO GMP, or PIC/S, are essential for ensuring product quality and are typically required for importation. (moh.gov.sg)

3Quality & Labeling

Inova Pharmaceuticals(singapore) PT — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Inova Pharmaceuticals' focus on Ayurvedic & Herbal Products (63.2%) and Respiratory & OTC (36.8%) therapeutic categories aligns with market demand for natural and over-the-counter remedies. The top five imported products, including Extract ($402,000 USD) and Bromhexine ($234,000 USD), reflect this strategic emphasis. The substantial import value of these products indicates a strong market presence and consumer preference for these therapeutic areas. This strategy positions Inova Pharmaceuticals to cater to the growing demand for holistic and accessible healthcare solutions in Singapore.

2Sourcing Profile

Inova Pharmaceuticals' sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on specific products within the Ayurvedic & Herbal and Respiratory & OTC categories. This approach suggests a preference for established products with proven efficacy and market acceptance. The company's reliance on Indian suppliers indicates a strategic choice to leverage India's manufacturing capabilities and cost advantages. However, the concentrated nature of this sourcing strategy may expose Inova Pharmaceuticals to risks associated with supply chain disruptions or changes in market demand for these specific products.

3Market Positioning

Seller's Guide — How to Become a Supplier to Inova Pharmaceuticals(singapore) PT

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Inova Pharmaceuticals, particularly those offering products within the Ayurvedic & Herbal and Respiratory & OTC categories. By aligning their offerings with Inova Pharmaceuticals' strategic focus, Indian exporters can position themselves as potential suppliers. However, the concentrated nature of Inova Pharmaceuticals' sourcing strategy suggests that any new supplier would need to demonstrate a strong value proposition, including product quality, regulatory compliance, and competitive pricing, to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Inova Pharmaceuticals must ensure their products are registered with the Health Sciences Authority (HSA) in Singapore and comply with the Health Products Act and the Medicines Act. Possessing recognized Good Manufacturing Practice (GMP) certifications, such as EU GMP, WHO GMP, or PIC/S, is essential to meet quality standards. Additionally, products must undergo batch testing, stability studies, and adhere to labeling requirements in English, as specified by HSA regulations. Compliance with these standards is crucial for successful market entry and distribution in Singapore.

Frequently Asked Questions — Inova Pharmaceuticals(singapore) PT

What products does Inova Pharmaceuticals(singapore) PT import from India?

Inova Pharmaceuticals(singapore) PT imports 2 pharmaceutical products across 2 categories. Top imports: Extract ($402.1K), Bromhexine ($233.9K).

What is Inova Pharmaceuticals(singapore) PT's total pharmaceutical import value?

Inova Pharmaceuticals(singapore) PT's total pharmaceutical import value from India is $635.9K, based on 61 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Inova Pharmaceuticals(singapore) PT focus on?

Inova Pharmaceuticals(singapore) PT imports across 2 categories. The largest: Ayurvedic & Herbal Products (63.2%), Respiratory & OTC (36.8%).

Get Full Inova Pharmaceuticals(singapore) PT Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Inova Pharmaceuticals(singapore) PT

Inova Pharmaceuticals(singapore) PT — Import Portfolio & Supplier Network

What Products Does Inova Pharmaceuticals(singapore) PT Import?

Top Products by Import Value

Inova Pharmaceuticals(singapore) PT Therapeutic Categories — 2 Specializations